| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/HYPERTENSIONAHA.107.097790 |
| P8608 | Fatcat ID | release_gx3zdcurkbdljktjn4paoof6c4 |
| P932 | PMC publication ID | 3261612 |
| P698 | PubMed publication ID | 18259044 |
| P50 | author | Susan M. Ramin | Q110252023 |
| Shakil Ahmad | Q43177725 | ||
| P2093 | author name string | Asif Ahmed | |
| Yang Xia | |||
| Tiejuan Mi | |||
| Rodney E Kellems | |||
| Mary-Clare Day | |||
| Shahrzad Abbasi | |||
| Cissy Chenyi Zhou | |||
| Lingwei Xia | |||
| P2860 | cites work | Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? | Q24561702 |
| Angiotensin receptors, autoimmunity, and preeclampsia | Q24605647 | ||
| A conserved family of calcineurin regulators. | Q27933946 | ||
| A calcineurin-dependent transcriptional pathway for cardiac hypertrophy | Q28269300 | ||
| Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide | Q28350767 | ||
| Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice | Q28504776 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Plasma active renin, angiotensin I, and angiotensin II during pregnancy and in preeclampsia | Q74195115 | ||
| A pressor substance (hysterotonin) occurring in toxemia | Q78778797 | ||
| Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences | Q79260245 | ||
| Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies | Q80379702 | ||
| Antiangiogenic effect of soluble vascular endothelial growth factor receptor-1 in placental angiogenesis | Q80410160 | ||
| Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 | ||
| Plasma renin, renin substrate, angiotensin II, and aldosterone in hypertensive disease of pregnancy | Q93732540 | ||
| Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review. | Q33930029 | ||
| Pre-eclampsia | Q34079933 | ||
| A study of angiotensin II pressor response throughout primigravid pregnancy | Q34512573 | ||
| Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. | Q34702420 | ||
| The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature | Q35002391 | ||
| Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia | Q35681821 | ||
| Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy | Q35699115 | ||
| Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome | Q35750283 | ||
| Localization of the angiotensin II and its receptor subtype expression in human endometrium and identification of a novel high-affinity angiotensin II binding site | Q35752519 | ||
| Role of the renin-angiotensin system in the pathogenesis of preeclampsia | Q36064478 | ||
| Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction | Q36228832 | ||
| The renin-angiotensin-aldosterone system in preeclampsia. A review | Q36453940 | ||
| Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? | Q37366512 | ||
| Cellular localization of AT1 receptor mRNA and protein in normal placenta and its reduced expression in intrauterine growth restriction. Angiotensin II stimulates the release of vasorelaxants | Q37377636 | ||
| Angiotensin II levels in hypertensive and normotensive pregnancies | Q37664263 | ||
| Toxemia: new concepts in an old disease | Q39559348 | ||
| Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia | Q40530224 | ||
| Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation | Q40735093 | ||
| IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. | Q40934953 | ||
| Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. | Q41091104 | ||
| Catecholamines. Their role in pregnancy and the development of pregnancy-induced hypertension | Q41109219 | ||
| Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta | Q41385756 | ||
| Placental cytokines and the pathogenesis of preeclampsia | Q41452017 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
| AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 | ||
| Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation | Q45069619 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| Endothelial dysfunction in preeclampsia | Q47879591 | ||
| Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia | Q47915288 | ||
| Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award | Q48348609 | ||
| Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. | Q51037240 | ||
| Raised serum TNF-alpha, blood sugar and uric acid in preeclampsia in third trimester of pregnancy. | Q51501322 | ||
| Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. | Q52933863 | ||
| Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR-1) Levels in Women with Preeclampsia | Q56619500 | ||
| Dysregulation of the Circulating and Tissue-Based Renin-Angiotensin System in Preeclampsia | Q56981959 | ||
| Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1 | Q57105968 | ||
| Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia | Q58778301 | ||
| Platelet angiotensin II binding and plasma renin concentration, plasma renin substrate and plasma angiotensin II in human pregnancy | Q59368198 | ||
| A Vascular Endothelial Growth Factor Antagonist Is Produced by the Human Placenta and Released into the Maternal Circulation1 | Q61479346 | ||
| Renin, angiotensin II, aldosterone, catecholamines, prostaglandins and vasopressin. The importance of pressor and depressor factors for hypertension in pregnancy | Q70391984 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pre-eclampsia | Q61335 |
| autoantibody | Q785022 | ||
| maternal health | Q6786626 | ||
| P304 | page(s) | 1010-1019 | |
| P577 | publication date | 2008-02-07 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling | |
| P478 | volume | 51 |
| Q27003069 | A leading role for the immune system in the pathophysiology of preeclampsia |
| Q53700889 | AT1-AA (Angiotensin II Type 1 Receptor Agonistic Autoantibody) Blockade Prevents Preeclamptic Symptoms in Placental Ischemic Rats. |
| Q38118625 | Activating autoantibodies and cardiovascular disease |
| Q35994304 | Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats |
| Q37800883 | Aetiology and physiopathology of preeclampsia and related forms |
| Q36355165 | Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia |
| Q37935034 | Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia |
| Q37353499 | Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension |
| Q27027039 | Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond |
| Q35701236 | Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice |
| Q33748680 | Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity |
| Q34040304 | Angiotensin receptor agonistic autoantibody-mediated soluble fms-like tyrosine kinase-1 induction contributes to impaired adrenal vasculature and decreased aldosterone production in preeclampsia |
| Q33748650 | Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia |
| Q33765684 | Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients |
| Q46300987 | Animal models of preeclampsia: translational failings and why. |
| Q37307973 | Are we getting closer to a Nobel prize for unraveling preeclampsia? |
| Q34618522 | Association between the presence of autoantibodies against adrenoreceptors and severe pre-eclampsia: a pilot study |
| Q37348150 | Association of autoantibodies against the M2-muscarinic receptor with perinatal outcomes in women with severe preeclampsia |
| Q50077615 | Autoantibodies against angiotensin and adrenergic receptors: more than a biomarker? |
| Q35715914 | Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia |
| Q34040357 | Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia |
| Q36528002 | Control of soluble fms-like tyrosine-1 (sFlt-1) production response to placental ischemia/hypoxia: role of tumor necrosis factor-α. |
| Q34731047 | Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsia |
| Q37996960 | Dynamic proteome in enigmatic preeclampsia: an account of molecular mechanisms and biomarker discovery |
| Q95362739 | Effect of Nigella sativa Ethanol Extract on the Nitric Oxide Content and Renal Arteriole Diameter of a Pre-eclampsia Mouse Model |
| Q46901141 | Electrochemical-surface enhanced Raman spectroscopy (E-SERS) of uric acid: a potential rapid diagnostic method for early preeclampsia detection |
| Q36245112 | Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications |
| Q33740993 | Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia |
| Q38056887 | From preeclampsia to renal disease: a role of angiogenic factors and the renin-angiotensin aldosterone system? |
| Q37217233 | How should women with pre-eclampsia be followed up? New insights from mechanistic studies |
| Q35029700 | Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes |
| Q34025660 | Hypertension, inflammation and T lymphocytes are increased in a rat model of HELLP syndrome |
| Q53433801 | Identification of a Novel Agonist-Like Autoantibody in Preeclamptic Patients. |
| Q37786350 | Immunologic characteristics of preeclampsia, a comprehensive review |
| Q37850374 | Inflammatory pattern recognition receptors and their ligands: factors contributing to the pathogenesis of preeclampsia |
| Q36241932 | International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. |
| Q36050775 | Is preeclampsia an autoimmune disease? |
| Q90106114 | Letter to the Editor: Importance of B cells in response to placental ischemia |
| Q38543831 | Linking the old and new -- do angiotensin II type 1 receptor antibodies provide the missing link in the pathophysiology of preeclampsia? |
| Q37211008 | Mechanisms and potential therapies for preeclampsia |
| Q33349894 | Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia |
| Q58911048 | Molecular mechanisms of preeclampsia |
| Q37024446 | Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. |
| Q37199922 | Pathogenesis and promising non-invasive markers for preeclampsia |
| Q24649934 | Pathophysiology of placentation abnormalities in pregnancy-induced hypertension |
| Q35045834 | Placenta-specific miRNA (miR-512-3p) targets PPP3R1 encoding the calcineurin B regulatory subunit in BeWo cells |
| Q37451544 | Placental Ischemia and Resultant Phenotype in Animal Models of Preeclampsia |
| Q90259719 | Placental Origins of Preeclampsia: Potential Therapeutic Targets |
| Q37278804 | Potential markers of preeclampsia--a review |
| Q37362662 | Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection |
| Q37879823 | Pregnancy-associated homeostasis and dysregulation: lessons from genetically modified animal models |
| Q42701351 | Progress toward identifying potential markers for preeclampsia: role of agonistic autoantibody to the angiotensin II type I receptor |
| Q36537709 | RAS in Pregnancy and Preeclampsia and Eclampsia |
| Q34404445 | Recent insights into the pathophysiology of preeclampsia |
| Q35707881 | Receptor-activating autoantibodies and disease: preeclampsia and beyond |
| Q35683468 | Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice |
| Q35363716 | Regulation of soluble fms-like tyrosine kinase-1 production in response to placental ischemia/hypoxia: role of angiotensin II. |
| Q92071252 | Renal natural killer cell activation and mitochondrial oxidative stress; new mechanisms in AT1-AA mediated hypertensive pregnancy |
| Q35743816 | Renin angiotensin signaling in normal pregnancy and preeclampsia |
| Q64907090 | Renin-angiotensin system in pre-eclampsia: everything old is new again. |
| Q34254466 | Sera from preeclampsia patients elicit symptoms of human disease in mice and provide a basis for an in vitro predictive assay |
| Q37042332 | Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia |
| Q37218199 | Systemic and uteroplacental renin--angiotensin system in normal and pre-eclamptic pregnancies |
| Q34169819 | Targeted expression of Cre recombinase provokes placental-specific DNA recombination in transgenic mice |
| Q36716822 | The Role of PPARs in Placental Immunology: A Systematic Review of the Literature |
| Q33591058 | The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia |
| Q36407259 | The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy |
| Q37039872 | The functional role of the renin-angiotensin system in pregnancy and preeclampsia |
| Q38014802 | The pathophysiology of preeclampsia involves altered levels of angiogenic factors promoted by hypoxia and autoantibody-mediated mechanisms |
| Q35591704 | The relevance of the Renin-Angiotensin system in the development of drugs to combat preeclampsia. |
| Q37041658 | The role of angiogenic, anti-angiogenic and vasoactive factors in pre-eclamptic African women: early- versus late-onset pre-eclampsia |
| Q33834419 | The role of inflammation in the pathology of preeclampsia |
| Q33668328 | The therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and statins for treatment of preeclampsia |
| Q38116097 | Tumor necrosis factor-alpha, interleukin-6, and interleukin-10 levels are altered in preeclampsia: a systematic review and meta-analysis. |
| Q38124456 | Vascular dysfunction in preeclampsia |
| Q36699839 | Vitamin D supplementation improves pathophysiology in a rat model of preeclampsia |
Search more.